Amycretin (Zenagamtide): The Next Generation of Weight-Loss Research
Meet amycretin, also known as zenagamtide, Novo Nordisk’s investigational GLP-1 and amylin receptor agonist. Explore the latest clinical trial results, its potential for weight loss and diabetes, and how it differs from other emerging metabolic medications.